Biogen’s drug approval in Alzheimer’s spurs two FDA advisers to resign

Joel Perlmutter, a neurologist at the Washington University of St. Louis, and David Knopman, a neurologist at the Mayo Clinic, both said they were disappointed that the agency had essentially ignored the recommendation of the advisory committee.
Click here to view original post